Scarica l'app Stockscreener
103.04
0.02%
-0.02
Dopo l'orario di chiusura:
103.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$103.06
Aprire:
$102.48
Volume 24 ore:
964.84K
Relative Volume:
0.89
Capitalizzazione di mercato:
$205.78B
Reddito:
$49.94B
Utile/perdita netta:
$17.60B
Rapporto P/E:
27.70
EPS:
3.72
Flusso di cassa netto:
$12.51B
1 W Prestazione:
-2.49%
1M Prestazione:
-12.07%
6M Prestazione:
+0.46%
1 anno Prestazione:
+8.57%
Intervallo 1D:
$102.41
$103.42
Intervallo di 1 settimana:
$102.41
$105.23
Portata 52W:
$92.35
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
Nome
Novartis Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NVS | 103.04 | 205.78B | 49.94B | 17.60B | 12.51B | 3.72 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-09-03 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-19 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-23 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-09-25 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-05 | Aggiornamento | Stifel | Hold → Buy |
| 2022-09-15 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-05-09 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Ripresa | Citigroup | Buy |
| 2021-12-14 | Downgrade | Redburn | Buy → Neutral |
| 2021-12-06 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Iniziato | Bernstein | Mkt Perform |
| 2021-03-10 | Downgrade | Argus | Buy → Hold |
| 2021-02-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2020-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-03-10 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-04-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-04-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2018-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Reiterato | Leerink Partners | Outperform |
| 2017-12-06 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Iniziato | Liberum | Buy |
Mostra tutto
Novartis Ag Adr Borsa (NVS) Ultime notizie
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - GlobeNewswire Inc.
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis
Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart
Chemical Biology in Biomedical Research - Novartis
Radioligand therapy: delivering now, building for the future - Novartis
Novartis at ASH - Novartis
Novartis 2022 Financial Results - Novartis
Novartis Financial Results – Q2 2023 - Novartis
Translational medicine research at Novartis - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Inclusivity - Novartis
Collaborations - Novartis
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart
21 Best Healthcare Companies to Invest In - Morningstar
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise
Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
NVS: 3 European Stocks to Watch as the EU Economy Strengthens - StockNews.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar
Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart
Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart
North America Immune Health Supplements Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News
Novartis lower as BofA downgrades on risks to valuation - MSN
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.
Morgan Stanley cuts Novartis rating amid limited innovation - Baystreet.ca
Spain Congestive Heart Failure Drugs Market Size & Outlook, 2030 - Grand View Research
Novartis Ag Adr Azioni (NVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.26%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):